Engflag

Glukoza Baxter

Quick links to important sections

Glukoza Baxter

Glukoza Baxter_EN

Method of action: Detoxifying, Hydrating

Treatment option: Coma, Parenteral Nutrition, Delivery, Renal Failure

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glukoza Baxter

Quick Facts

Property Description
Active Ingredient Dextrose (D-glucose monohydrate)
Form Sterile Solution for Intravenous Infusion
Pharmacological Class Caloric Agent and Fluid Replenisher
General Purpose Provides energy (calories) and hydration
Origin Naturally derived simple sugar (monosaccharide)

What type of medicine is Glukoza Baxter and its Pharmacological Class?

Glukoza Baxter is a sterile, nonpyrogenic solution for infusion administered through the intravenous (IV) route, whose active substance is Dextrose. The solution is clinically recognized for its dual function as a Caloric Agent and a Parenteral Fluid Replenisher. The solution is provided in a specialized, sterile fluid container, typically a flexible plastic bag, ensuring safe and contained delivery for patients unable to sustain oral intake. Glukoza Baxter, as a specific brand formulation, is utilized across various clinical settings due to its established method of delivering Dextrose.

Dextrose: Composition, Origin, and General Purpose

The active component, Dextrose (D-glucose monohydrate), is a simple sugar, or monosaccharide, structurally identical to the natural glucose found in the human body. This ingredient is combined with sterile Water for Injections. The fundamental purpose of the infusion is to supply the body with a readily available source of carbohydrate calories and essential hydration. This function is critical during periods when a patient requires fluid replacement or supplemental energy, supporting basal metabolic needs and contributing to the maintenance of the body's overall fluid balance. Furthermore, the simple composition of Dextrose solution allows it to frequently function as a sterile vehicle for diluting and delivering other compatible IV medications.

Regulatory References

  1. New Zealand Medsafe Data Sheet

What side effects are possible with Glukoza Baxter?

Possible Side Effects and Safety Information

The safety profile for Glukoza Baxter (Dextrose Injection) is focused on reactions related to fluid, glucose, and electrolyte balance, as documented in official regulatory labeling.

Documented Adverse Reactions

Adverse effects are primarily grouped into the following System-Organ Classes:

  • Metabolism and Nutrition Disorders: The most common risks involve imbalances, including hyperglycemia (high blood sugar), hyponatremia (low sodium), and fluid overload.
  • General Disorders and Administration Site Conditions: Reactions localized to the infusion site, such as pain, irritation, swelling, or phlebitis (vein inflammation), are frequently observed.
  • Immune System Disorders: Allergic reactions, ranging from mild hypersensitivity to severe anaphylactoid reactions, are documented.

Serious Safety Concerns

Specific clinically significant and potentially life-threatening adverse reactions are noted in regulatory information:

  • Acute Hyponatremic Encephalopathy: A severe form of brain swelling resulting from acute symptomatic hyponatremia, especially concerning in vulnerable patient populations.
  • Hyperosmolar Hyperglycemic State: A serious metabolic complication from excessive glucose administration.

Population and Use Restrictions

Safety statements identify patients who require particular caution or for whom the product may be restricted:

  • Contraindications: Use is restricted in patients with known allergy to dextrose or corn products, and those with clinically significant hyperglycemia or uncompensated diabetes.
  • Vulnerable Populations: Neonates, infants, and children are at increased risk for severe hypo- or hyperglycemia and subsequent hyponatremic encephalopathy, requiring close monitoring. Specific warnings also apply to use during labor and in patients with reduced cerebral compliance.

The regulatory safety information emphasizes that the risk of these effects is heightened by improper administration or pre-existing conditions that affect glucose and fluid management.

Overdose and Emergency Response

Overdose and when to seek help

The officially documented overdose profile for Dextrose solution is defined by the consequences of excessive fluid and carbohydrate administration, particularly when the infusion rate exceeds the body's ability to process them.

Documented Overdose Manifestations

Overdose presentations documented in regulatory sources include Hyperglycemia (high blood sugar), Hyperosmolar Hyperglycemic State/Syndrome, and Fluid and Solute Overload (Hypervolemia), which may lead to Pulmonary Oedema or Congested States. Signs of electrolyte imbalance, such as Acute Hyponatraemia (low sodium), are also noted.

Overdose signs may also include mental confusion, loss of consciousness, seizures, headache, nausea, and vomiting.

Serious Outcomes and Urgent Action

Official labeling indicates that unmanaged or excessive administration can result in Coma and Death. The risk of severe, life-threatening neurological injury is highlighted, especially the progression of hyponatraemia to Acute Hyponatraemic Encephalopathy (brain oedema).

When to seek immediate medical help: The presence of severe symptoms such as loss of consciousness, seizures, or breathing difficulty requires urgent medical attention.

Emergency Response: Regulatory instructions mandate the immediate discontinuation of the infusion if an overdose or adverse reaction occurs, followed by the institution of appropriate therapeutic countermeasures (symptomatic and supportive treatment).

Monitoring and Specific Risks

Management of overdose requires close and frequent monitoring of blood glucose levels and blood electrolyte concentrations. Individuals at increased risk of severe, life-threatening complications like hyponatraemic encephalopathy include children, elderly patients, and women of childbearing potential.

Therapeutic Uses of Glukoza Baxter

What Glukoza Baxter Treats: Main Uses and Benefits

Glukoza Baxter (Dextrose solution) is commonly used to provide supportive metabolic assistance and fluid replacement, which assists with managing energy and hydration needs in relevant clinical situations. These solutions are a source of water and calories.

A key application is to manage acute symptomatic episodes of hypoglycemia (low blood sugar), which can be characterized by confusion and weakness. It is also applied when patients cannot sustain adequate oral intake, supporting fluid replacement and supplying essential carbohydrate calories for nutritional support. The solution is relevant in situations where patients experience hyperkalemia (high potassium levels) and is used for Total Parenteral Nutrition (TPN).

“This solution is relevant for easing symptoms that are linked to acute metabolic imbalance, providing support that assists with energy and volume deficits.”

This therapy assists with reversing acute neurological symptoms related to energy deprivation and may help maintain functional stability, supporting general well-being during symptomatic phases.

Quick Fact: Support for Acute Metabolic Stress Symptoms
Symptom Focus Confusion, weakness, fluid volume deficit, and nutrient deprivation symptoms.
Therapeutic Benefit Used to help restore depressed blood glucose levels and assist in providing water/calories.
Clinical Scenario Commonly used in emergency care for acute hypoglycemia and for nutritional support post-surgery/illness.
Patient Benefit May assist with mitigating risk during high-potassium treatment and supports the body in managing ketosis.

Regulatory References

  1. FDA Dextrose Injection Prescribing Information

Eligibility and Restrictions for Use

Official Eligibility Profile: Glukoza Baxter (Dextrose Infusion)

The official regulatory labels define eligibility based primarily on a patient’s metabolic and fluid status, and specific vulnerabilities in age or organ function.

Contraindications (Must Not Use)

Classification Prohibited Populations/Conditions
Absolute Clinically significant hyperglycemia (high blood sugar) and known hypersensitivity to dextrose or corn products.
Fluid/Volume Patients with severe dehydration (for hypertonic solutions) or extracellular hyperhydration (fluid overload).
Specific Trauma Patients with intracranial or intraspinal hemorrhage (for higher concentrations).

Conditional Use and Restrictions

Population/Condition Regulatory Requirement (Use with Caution)
Age Groups Neonates and low birth weight infants require particular caution due to increased risk of fluid and glucose imbalances. Elderly patients require cautious selection of dosage due to a higher likelihood of decreased organ function.
Organ Function Use with caution in patients with impaired renal function or in those at risk for hyponatremia (low sodium). Patients with diabetes mellitus or impaired glucose tolerance must be closely monitored.
Pregnancy/Lactation Administration during pregnancy should occur only if clearly needed. Caution must be exercised when administering to a nursing mother.

What should I know about interactions with other medicines?

Interaction Scope

Category Interacting Agents Interaction Outcome
Pharmacodynamic Interactions Drugs affecting Glycemic or Fluid/Electrolyte Control May necessitate monitoring of blood glucose, serum electrolytes, and acid-base balance.
Increased Hyponatremia Risk Diuretics, SSRIs, SNRIs, Vasopressin Analogs, and certain cytotoxic/psychotropic drugs Co-administration increases the risk of developing hyponatremia and acute hyponatremic encephalopathy.

Timing and Contraindication Restrictions The 50% solution of Glukoza Baxter is formally contraindicated in patients with the condition of Alcohol Withdrawal. This restriction is documented due to the potential risk of precipitating Wernicke encephalopathy in individuals with underlying thiamine deficiency.

A critical procedural constraint is that the solution must not be administered simultaneously with Blood Products (such as packed red blood cells) through the same intravenous administration set. This is a rule of physical incompatibility intended to prevent the occurrence of pseudoagglutination or hemolysis.

Population-Specific Notes Official labeling notes that the risk associated with the hyponatremia interaction is explicitly heightened in both Younger Pediatric Patients and Geriatric Patients when they are co-administered drugs known to affect sodium levels.

Connection to the Overall Interaction Profile Regulatory documents define the product’s interaction structure primarily through documented pharmacodynamic effects related to its metabolic function, alongside necessary procedural prohibitions related to physical compatibility during administration.

Mechanism of Action

How Glukoza Baxter Works (Mechanism of Action)

Glukoza Baxter provides D-glucose substrate for cellular respiration by delivering Dextrose (glucose) directly into the circulation. The intravenous administration bypasses gastrointestinal absorption. Subsequent transport across the plasma membrane into most cells is mediated by glucose transporter proteins (GLUTs).

Core Metabolic Cascade

The entry of D-glucose into the cell leads to the initiation of glycolysis. The mechanism involves immediate phosphorylation by hexokinase, forming glucose-6-phosphate, the initial intermediate of the glycolytic pathway. The D-glucose substrate is quickly metabolized to ATP and is utilized as a source of energy to fulfill metabolic requirements.

Pathway Modulation

The availability of D-glucose as an oxidative substrate reduces the mobilization of endogenous substrates. The increase in available cellular glucose shifts metabolism away from lipid breakdown and inhibits fatty acid beta-oxidation.

Dosage and Administration Information

Glukoza Baxter is administered intravenously by a healthcare professional. The specific dosage, concentration (e.g., 5%, 10%, 50%), and rate of infusion are determined by a physician, based on the patient's age, weight, clinical condition, and the reason for treatment.

Method of Administration

  • Intravenous Route: The solution is given directly into a vein, typically through a plastic tube attached to a needle in the arm, or via a central venous line for hypertonic solutions (concentrations of 10% or higher). Administration of highly concentrated (hyperosmolar) solutions into a peripheral vein is generally not recommended as it may cause local venous irritation or phlebitis.
  • Aseptic Technique: Strict aseptic technique must be followed during preparation and administration to prevent contamination. The solution should be inspected visually before use for particles or discoloration; if either is present, the solution must be discarded.

Monitoring During Infusion

Close clinical and laboratory monitoring is essential, particularly for fluid balance, serum sodium levels, and blood glucose concentration.

  • Blood Glucose: As this is a glucose solution, blood sugar levels may increase (hyperglycemia). If this occurs, the infusion rate may need to be adjusted, or insulin may be required.
  • Electrolytes: Monitoring of plasma electrolytes, especially sodium, is crucial due to the risk of low sodium levels (hyponatremia), which can be exacerbated by glucose administration.

Important Considerations

Glukoza Baxter should not be administered through the same tubing as a blood transfusion, as this can lead to damage or clumping of red blood cells. The solution is for single-use only, and any unused portion must be discarded.

Recent Clinical Evidence

Research Evidence for Glukoza Baxter (Dextrose Solution)

This section provides an overview of the structured research that has been studied for Dextrose solution in its primary clinical applications, describing the types of studies, the patterns observed in the data, and what areas remain uncertain.

Evidence for Acute Blood Sugar Correction

Studies primarily consist of short-term Randomized Controlled Trials (RCTs) and systematic reviews involving adult and pediatric patients with low blood glucose. Researchers monitored outcomes describing episodic changes, such as the time taken for blood glucose levels to reach a target range, and observations of neurological status. Research describes measurements of the speed at which blood glucose levels changed after administration. However, long-term effects regarding the durability of blood sugar stability following this immediate correction are not fully established, as existing studies focus consistently on the acute response.

Evidence for Supportive Caloric and Fluid Replacement

The research supporting the use of Dextrose solution for providing supportive calories and fluid balance is based on foundational physiological studies and fluid management guidelines. These investigations tracked the solution's role in maintaining fluid balance, electrolyte levels, and measuring the provision of carbohydrate calories as part of metabolic support. Research indicates that Dextrose solutions are a measurable source of water and calories. The use of Dextrose in this role is a widely described practice, though certainty remains low regarding the most optimal balance of components in prolonged, high-volume fluid therapy.

Evidence in Complex Metabolic Support Scenarios

Dextrose solution was evaluated in more complex scenarios, including systematic reviews of Total Parenteral Nutrition (TPN) and trials exploring its use with insulin for high potassium levels (hyperkalemia). Studies explored outcomes monitoring physiological stress in critically ill patients, a group that often experiences acute episodes. Findings were mixed regarding the relationship between Dextrose load and high blood sugar in critically ill subjects. Data for optimal Dextrose dosing in these unstable populations remain insufficient and are often confounded by the severity of the primary illness.

Key Studies & References

  1. Dextrose Injection, USP (Prescribing Information) – U.S. National Library of Medicine (DailyMed)
  2. Glucose and Insulin for the Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about Glukoza Baxter (FAQ)

Q: What is Glukoza Baxter used for?

Glukoza Baxter is a solution containing glucose (dextrose). It is typically administered to patients who may require fluids or a source of energy through an intravenous route. It may also be used to treat low blood sugar (hypoglycemia) in a supervised setting.

Q: How does Glukoza Baxter provide energy?

The body processes the glucose in the solution. Glucose is a simple sugar that is a key source of energy for the body's cells, including those in the brain and muscles.

Q: What are the potential effects of receiving this solution?

Receiving the solution may contribute to restoring fluid balance and increasing the sugar levels in the bloodstream. Trained healthcare professionals monitor patients for potential effects, which may include changes in fluid status or blood sugar concentration.

How should Glukoza Baxter be stored and disposed of?

Storage and Disposal Conditions for Glukoza Baxter

Official labeling mandates that Glukoza Baxter must be stored at room temperature, typically 25 C (77 F), and protected from freezing. The container, sealed in an overpouch, must not be removed from the overwrap until the product is ready for use, and it must be visually inspected for particulate matter before administration. The product is for single use only. Partially used containers must not be stored or reconnected and must be discarded immediately. Any unused solution and associated waste materials must be disposed of strictly in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagSlovenia

Equivalent of Glukoza Baxter found in:

A-Z Index: